The Japan Patent Office has granted PolTREG a patent for the intrathecal administration of its proprietary PTG-007 Treg cellular therapy for multiple sclerosis.
Injecting Treg cells directly in the spinal fluid – and not in the bloodstream – has shown superior results, PolTREG has found in its earlier studies in treating neurodegenerative diseases, as it bypasses the blood-brain barrier.
PolTREG is planning to launch two Phase 1/2a clinical trials for PTG-007, one in each of two forms of multiple sclerosis (MS): relapsing-remitting MS and primary-progressive MS.
PolTREG received a flurry of patents late last year as it continues to explore the full potential of Treg cells in fighting a flurry of autoimmune diseases.
2025-01-09
PolTREG obtains Japanese patent for intrathecal PTG-007 therapy in multiple sclerosis
See other news
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.